Amgen's cholesterol drug Repatha has been given the green light in Europe, making it the first in the new PCSK9 inhibitor class approved anywhere in the world. Repatha (evolocumab) is a human ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

The drugmaker said Repatha would start with a list price of $14,100 for a year’s worth of treatment. Developed by Amgen’s scientists, it is the second in a new class of drugs that lower ...

Amgen had earlier begun individual negotiations with insurers, reducing the price of Repatha to the Harvard Pilgrim health plan, for example, and agreeing to refund the cost of the drug to any ...

THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ -- Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes ( ...

Amgen’s Repatha and Sanofi/Regeneron’s Praluent are competing for market share in the new class of PCSK9 inhibitors for high-risk cholesterol patients after both were approved by FDA this summer.

Results from the long-awaited Fourier trial, designed to test Amgen’s Repatha as a tool to cut cardiovascular risks, showed that the drug cut heart attack risks by 27% over the course of the ...

In the dispute with Sanofi and partner Regeneron, whose cholesterol-lowering monoclonal antibody drug Praluent works in a similar way as Repatha, Amgen wants the court to rule on how much ...

Federal Circuit invalidated patents on blockbuster Amgen cholesterol drug U.S. Solicitor General says decision was reasonable (Reuters) - The Biden Administration told the U.S. Supreme Court on ...